System and method to deliver therapy in presence of another therapy

Information

  • Patent Grant
  • 9504836
  • Patent Number
    9,504,836
  • Date Filed
    Tuesday, July 8, 2014
    11 years ago
  • Date Issued
    Tuesday, November 29, 2016
    9 years ago
Abstract
Various aspects relate to a method. In various embodiments, a therapy of a first therapy type is delivered, and it is identified whether a therapy of a second therapy type is present to affect the therapy of the first therapy type. Delivery of the therapy is controlled based on the presence of the therapy of the second therapy type. Some embodiments deliver the therapy of the first type using one set of parameters in the presence of a therapy of a second type, and deliver the therapy of the first type using another set of parameters when the therapy of the second type is not present. In various embodiments, one of the therapy types includes a cardiac rhythm management therapy, and the other includes a neural stimulation therapy. Other aspects and embodiments are provided herein.
Description
TECHNICAL FIELD

This application relates generally to medical devices and, more particularly, to systems, devices and methods to control the delivery of therapy.


BACKGROUND

Different types of therapies can be delivered simultaneously, or near simultaneously, to treat the same condition or to treat different conditions. For example, it possible to deliver both neural stimulation (NS) therapy and cardiac rhythm management (CRM) therapy.


Some NS therapy can alter cardiac contractility and excitability. Direct electrical stimulation of parasympathetic nerves can activate the baroreflex, inducing a reduction of sympathetic nerve activity and reducing blood pressure by decreasing vascular resistance. Sympathetic inhibition, as well as parasympathetic activation, have been associated with reduced arrhythmia vulnerability following a myocardial infarction, presumably by increasing collateral perfusion of the acutely ischemic myocardium and decreasing myocardial damage. Modulation of the sympathetic and parasympathetic nervous system with neural stimulation has been shown to have positive clinical benefits, such as protecting the myocardium from further remodeling and predisposition to fatal arrhythmias following a myocardial infarction.


SUMMARY

Various aspects of the present subject matter relate to a device. In various embodiments, the device comprises at least one port to connect to at least one lead with at least one electrode, stimulator circuitry connected to the at least one port and adapted to deliver electrical pulses to at least one of the electrodes as part of a first electrical therapy type, and a controller connected to the stimulator circuitry. The controller is adapted to control delivery of the electrical pulses using a plurality of parameters for at least one programmed electrical therapy of the first electrical therapy type. The controller is adapted to determine when a therapy of a second electrical therapy type is applied, provide electrical therapy for the first electrical therapy type using a first set of parameters when the therapy of the second electrical therapy type is present to affect the at least one programmed electrical therapy for the first electrical therapy type, and provide electrical therapy using a second set of parameters when the therapy of the second electrical therapy type is not present.


Various aspects of the present subject matter relate to a method. In various embodiments, a therapy of a first therapy type is delivered, and it is identified whether a therapy of a second therapy type is present to affect the therapy of the first therapy type. Delivery of the therapy is controlled based on the presence of the therapy of the second therapy type. Some embodiments deliver the therapy of the first type using one set of parameters in the presence of a therapy of a second type, and deliver the therapy of the first type using another set of parameters when the therapy of the second type is not present.


In various embodiments, the first therapy type includes a cardiac rhythm management therapy, and the second therapy type includes a neural stimulation therapy. In various embodiments, the first therapy type includes a neural stimulation therapy and the second therapy type includes a cardiac rhythm management therapy.


This Summary is an overview of some of the teachings of the present application and not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and appended claims. Other aspects will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof, each of which are not to be taken in a limiting sense. The scope of the present invention is defined by the appended claims and their equivalents.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a system including an implantable medical device (IMD) and a programmer, according to various embodiments.



FIG. 2 illustrates an embodiment of CRM device, such as can be used in an IMD in the system of FIG. 1.



FIG. 3 illustrates a programmer, such as the programmer illustrated in the system of FIG. 1, or other external device to communicate with the implantable medical device(s), according to various embodiments.



FIG. 4 illustrates a system diagram of an embodiment of an implantable medical device configured for multi-site stimulation and sensing.



FIG. 5 illustrates an implantable medical device (IMD) such as shown in FIG. 1 having a neural stimulation (NS) component and cardiac rhythm management (CRM) component, according to various embodiments.



FIG. 6 illustrates a system including a programmer, an implantable neural stimulator (NS) device and an implantable cardiac rhythm management (CRM) device, according to various embodiments.



FIG. 7 illustrates an implantable neural stimulator (NS) device such as can be incorporated as the IMD in the system of FIG. 1 or as the neural stimulator in the system of FIG. 6, according to various embodiments of the present subject matter.



FIG. 8 illustrates a device, according to various embodiments, such as the IMD illustrated in FIG. 1, for example.



FIG. 9 illustrates a device, according to various embodiments, such as the IMD illustrated in FIG. 1, for example.



FIG. 10 illustrates a method, according to various embodiments.



FIG. 11A illustrates a method for controlling delivery of therapy of the first type (e.g. CRM therapy) based on a plurality of parameters organized into at least two sets and based on whether the therapy of the second type (e.g. neural stimulation therapy) is present, according to various embodiments.



FIG. 11B illustrates a method for controlling delivery of therapy of the first type (e.g. CRM therapy) based the intensity of the therapy of the second type (e.g. neural stimulation therapy), according to various embodiments.



FIG. 11C illustrates a method for controlling delivery of therapy of the first type (e.g. CRM therapy) based on whether the therapy of the second type (e.g. neural stimulation therapy) is present and on the intensity of the therapy of the second type, according to various embodiments.



FIGS. 12A, 12B and 12C illustrate plurality of parameters, and further illustrate the first and second sets of parameters, according to various embodiments.





DETAILED DESCRIPTION

The following detailed description of the present subject matter refers to the accompanying drawings which show, by way of illustration, specific aspects and embodiments in which the present subject matter may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the present subject matter. Other embodiments may be utilized and structural, logical, and electrical changes may be made without departing from the scope of the present subject matter. References to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope is defined only by the appended claims, along with the full scope of legal equivalents to which such claims are entitled.


The present subject matter relates to a device that delivers a therapy of a first therapy type, identifies whether a therapy of a second therapy type is present to affect the therapy of the first therapy type, and controls delivery of the therapy based on the presence of the therapy of the second therapy type and based on a plurality of parameters organized into a first set and a second set in at least one programmed therapy for the therapy type. Some embodiments of the present subject matter relates to a device that provides a cardiac rhythm management (CRM) type of therapy, such as a pacing therapy and various pacing modes, a defibrillation therapy, and a cardiac resynchronization therapy (CRT), and combinations thereof. The CRM type of therapy is provided in the presence of neural stimulation (NS) therapy. The CRM and NS therapy can be contained in the same device or in independent implantable devices that communicate through lead-based or leadless means.


In various embodiments, the CRM device detects, receives an alert or otherwise identifies the presence of neural stimulation, and switches from a first to a second set of pacing and/or defibrillation parameters to account for the presence of neural stimulation. It is known that some neural stimulation can alter, among other things, cardiac conduction, contractility and excitability. The use of the second set of parameters accounts for such changes induced by the neural stimulation.


In various embodiments, the neural stimulation device detects, receives an alert or otherwise identifies the presence of the CRM device, and switches from a first to a second set of neural stimulation parameters. CRM therapy captures cardiac tissue with electrical energy. The electrical energy itself can cause problems. An example of switching from a first set of parameter to a second set of parameters includes stimulating a different neural target, or changing a neural stimulation signal parameter, such as amplitude, frequency, burst timing and morphology, to compensate for the CRM therapy. Another example provides a neural stimulation therapy to cooperate with CRM therapy, such as by stimulating an SVC-AO cardiac fat pad to selectively control contractility for the heart, a PV cardiac fat pad associated with an sinoatrial (SA) node to selectively control a sinus rate, and/or an IVC-LA cardiac fat pad associated with an atrioventricular (AV) node to selectively control AV conduction. In humans, the SVC-AO cardiac fat pad is located proximate to a junction between a superior vena cava and an aorta, the PV cardiac fat pad is located proximate to a junction between a right atrium and right pulmonary vein, and the IVC-LA cardiac fat pad is located proximate to a junction between an inferior vena cava and left atrium. Because fat pad ganglia form part of the efferent pathway, stimulation of cardiac fat pads directly effects cardiac tissue. For example, stimulating the parasympathetic efferents can selectively affect rate, and conduction. Stimulation of the parasympathetic pathway also has post-ganglionic inhibition of sympathetic outflow. The cardiac fat pads can be stimulated with epicardial leads with electrodes placed in or near the target fat pad, with intravascularly-fed leads to transvascularly stimulate the target fat pad from within the vessel, and intravascularly fed leads to pierce through a vessel wall into the target fat pad. Neural pathways, such as the vagus nerve trunk and vagal cardiac branches, for example, can be stimulated using a nerve cuff, using an intravascularly-fed leads to transvascularly stimulate the neural target from within the vessel, and intravascularly-fed leads to pierce through a vessel wall into position proximate to a neural target. Baroreceptors within blood vessel walls can be stimulated using an intravascularly-fed lead and a stent-like electrode positioned proximate to the target baroreceptors.


According to various embodiments, the CRM device identifies the presence of neural stimulation (e.g. detects the neural stimulation or is alerted by the neural stimulation device). When neural stimulation is identified the device switches from its normal mode to a “neural stimulation mode.” In this mode, the device uses alternate settings for parameters such as V-V interval, A-V interval, anti-tachycardia pacing (ATP) rate, defibrillation threshold, etc. to adapt to the presence of neural stimulation. The second set of parameters are independently programmable in some embodiments. Some embodiments automatically relate the second set of parameters to the baseline parameters.


Since neural stimulation can alter cardiac conduction and excitability. Therefore, the appropriate CRM settings during neural stimulation may be different from the appropriate settings in the absence of neural stimulation. The present subject matter allows the CRM and neural stimulation devices to continuously provide appropriate therapy.


Various embodiments provide a system, either in one device or in more than one device, with capabilities to provide CRM and NS therapy, and with the capability to automatically adjust pacing and defibrillation parameters during neural stimulation to account for altered cardiac conditions. During neural stimulation, some embodiments switch to an alternate set of CRM parameters, compensating for cardiac changes caused by neural stimulation. Therefore, the system has two sets of pacing and defibrillation parameters. The parameters in the sets can be mutually or partially exclusive of each other. The parameters of one set can be a subset of the parameters in another. The sets can include the same parameters, but different values for one or more of the parameters. The second set could be independently programmable or automatically related to the baseline parameters.



FIG. 1 illustrates a system 100 including an implantable medical device (IMD) 101 and a programmer 102, according to various embodiments of the present subject matter. Various embodiments of the IMD 101 include neural stimulator functions only, various embodiments include CRM functions only, and various embodiments include a combination of NS and CRM functions. The IMD can be designed to deliver other therapies, such as drug therapies. The IMD and programmer are capable of wirelessly communicating data and instructions. In various embodiments, for example, the programmer and IMD use telemetry coils to wirelessly communicate data and instructions. Thus, the programmer can be used to adjust the programmed therapy provided by the IMD, and the IMD can report device data (such as battery and lead resistance) and therapy data (such as sense and stimulation data) to the programmer using radio telemetry, for example.



FIG. 1 illustrates an implantable medical device (IMD). Aspects of the present subject matter can be practiced using external devices. FIG. 1 also illustrates that IMD communicating with a programmer. The IMD can also wirelessly communicate directly with a personal digital assistant or other electronic device such as would be used in an advanced patient management (APM) system, which can organize and perform calculations based on recorded data, and later provide the data to a programmer.



FIG. 2 illustrates an embodiment of CRM device 203, such as can be used in an IMD in the system of FIG. 1. The illustrated device 203 includes a controller 204 connected to a memory 205. The figure further illustrates electrodes 206A and 206B connected to the device. According to the illustration, the electrodes 206A and 206B are connected to sense modules 207A and 207B to sense electrical signal at the electrode, and pulse generators 208A and 208B to generate stimulation signals to the electrodes. The controller 204 is connected to the sense modules 207A and 207B and the pulse generator modules 208A and 208B via interfaces 209A and 209B.


The memory includes data and instructions. The controller is adapted to access and operate the instructions to perform various functions within the device, including programmed CRM therapies. The memory 205 includes a plurality of parameters that are used to control the delivery of the therapy. The plurality of parameters are organized into at least two sets. A programmed therapy can be performed using either of the at least two sets of parameters. In various embodiments, the controller operates on the instructions to deliver a therapy, such as bradycardia pacing or defibrillation, of a CRM therapy type is delivered. The controller identifies whether a therapy of a second therapy type, such as a neural stimulation therapy, is present to affect the CRM therapy. Delivery of the CRM therapy is controlled based on the presence of the neural stimulation therapy type. Some embodiments deliver the CRM therapy using one set of parameters in the presence of a neural stimulation therapy and deliver the CRM therapy using another set of parameters when the neural stimulation therapy is not present.


A transceiver 210 is connected to the controller 204. The CRM device is capable of wireless communicating with a programmer, for example, using the transceiver 210. For example, various embodiments use telemetry coils to wirelessly communicate data and instructions. In other embodiments, communication of data and/or energy is by ultrasonic means.



FIG. 3 illustrates a programmer 311, such as the programmer 102 illustrated in the system of FIG. 1, or other external device to communicate with the implantable medical device(s), according to various embodiments of the present subject matter. An example of another external device includes Personal Digital Assistants (PDAs) or personal laptop and desktop computers in an Advanced Patient Management (APM) system. The illustrated device includes controller circuitry 312 and a memory 313. The controller circuitry is capable of being implemented using hardware, software, and combinations of hardware and software. For example, according to various embodiments, the controller circuitry includes a processor to perform instructions embedded in the memory to perform a number of functions, including communicating data and/or programming instructions to the implantable devices. The illustrated device 311 further includes a transceiver 314 and associated circuitry for use to communicate with an implantable device. Various embodiments have wireless communication capabilities. For example, various embodiments of the transceiver and associated circuitry include a telemetry coil for use to wirelessly communicate with an implantable device. The illustrated device 311 further includes a display 315, input/output (I/O) devices 316 such as a keyboard or mouse/pointer, and a communications interface 317 for use to communicate with other devices, such as over a communication network.


The programmer is able to program at least some of the parameters in one of the parameter sets used by the IMD to provide the therapy. In some embodiments, the IMD automatically determines the second set of parameters as a function of the programmed first set of parameters. In various embodiments, at least some of the parameters in both a first and second set of parameters is programmable.



FIG. 4 illustrates a system diagram of an embodiment of an implantable medical device configured for multi-site stimulation and sensing. This diagram provides another example of an IMD capable of performing a number of CRM type of therapies. Pacing, as used in the discussion of this figure, relates to electrical stimulation. In various embodiments, the stimulation for a given channel includes stimulation to capture myocardia, neural stimulation or both pacing and neural stimulation. Three examples of sensing and pacing channels are designated “A” through “C”. The illustrated channels comprise bipolar leads with ring electrodes 418A-C and tip electrodes 419A-C, sensing amplifiers 420A-C, pulse generators 421A-C, and channel interfaces 422A-C. Each of these channels thus includes a stimulation channel extending between the pulse generator, the electrode and a sensing channel extending between the sense amplifier and the electrode. The channel interfaces 422A-C communicate bidirectionally with microprocessor 423, and each interface may include analog-to-digital converters for digitizing sensing signal inputs from the sensing amplifiers and registers that can be written to by the microprocessor in order to output pacing pulses, change the pacing pulse amplitude, and adjust the gain and threshold values for the sensing amplifiers. The sensing circuitry detects a chamber sense, either an atrial sense or ventricular sense, when an electrogram signal (i.e., a voltage sensed by an electrode representing cardiac electrical activity) generated by a particular channel exceeds a specified detection threshold. Algorithms, including a number of adjustable parameters, used in particular stimulation modes employ such senses to trigger or inhibit stimulation, and the intrinsic atrial and/or ventricular rates can be detected by measuring the time intervals between atrial and ventricular senses, respectively. The AV conduction can be measured by measuring a time interval between atrial and ventricular intrinsic events.


The switching network 424 is used to switch the electrodes to the input of a sense amplifier in order to detect intrinsic cardiac activity and to the output of a pulse generator in order to deliver stimulation. The switching network also enables the device to sense or stimulate either in a bipolar mode using both the ring and tip electrodes of a lead or in a unipolar mode using only one of the electrodes of the lead with the device housing or can 425 serving as a ground electrode or another electrode on another lead serving as the ground electrode. A shock pulse generator 426 is also interfaced to the controller for delivering a defibrillation shock via a pair of shock electrodes 427 to the atria or ventricles upon detection of a shockable tachyarrhythmia. Channel interface 428 and sense amplifier 429 provide a connection between the microprocessor and the switch to receive a sensed signal from a sensor 430 for use to detect a second therapy type such as a neural stimulation therapy.


The controller or microprocessor controls the overall operation of the device in accordance with programmed instructions and a number of adjustable parameters stored in memory 431, including controlling the delivery of stimulation via the channels, interpreting sense signals received from the sensing channels, and implementing timers for defining escape intervals and sensory refractory periods. The controller is capable of operating the device in a number of programmed stimulation modes which define how pulses are output in response to sensed events and expiration of time intervals. Most pacemakers for treating bradycardia are programmed to operate synchronously in a so-called demand mode where sensed cardiac events occurring within a defined interval either trigger or inhibit a pacing pulse. Inhibited stimulation modes utilize escape intervals to control pacing in accordance with sensed intrinsic activity such that a stimulation pulse is delivered to a heart chamber during a cardiac cycle only after expiration of a defined escape interval during which no intrinsic beat by the chamber is detected. Escape intervals for ventricular stimulation can be restarted by ventricular or atrial events, the latter allowing the pacing to track intrinsic atrial beats. A telemetry interface 432 is also provided which enables the controller to communicate with an external programmer or remote monitor. Rather than or in addition to interface 428, sense amplifier 429 and sensor 430, some embodiments receive an alert or other communication through the telemetry interface or through other communication means to identify the presence of another type of therapy.



FIG. 5 illustrates an implantable medical device (IMD) 533 such as shown at 101 in FIG. 1 having a neural stimulation (NS) component 534 and cardiac rhythm management (CRM) component 535, according to various embodiments of the present subject matter. The illustrated device 533 includes a controller 536 and a memory 537. According to various embodiments, the controller includes hardware, software, or a combination of hardware and software to perform the baroreceptor stimulation and CRM functions. For example, the programmed therapy applications, including a plurality of parameters organized in at least two parameter sets, discussed in this disclosure are capable of being stored as computer-readable instructions embodied in memory and executed by a processor. According to various embodiments, the controller includes a processor to execute instructions embedded in memory to perform the baroreceptor stimulation and CRM functions. The illustrated device 533 further includes a transceiver 538 and associated circuitry for use to communicate with a programmer or another external or internal device. Various embodiments include a telemetry coil.


The CRM therapy section 535 includes components, under the control of the controller, to stimulate a heart and/or sense cardiac signals using one or more electrodes. The CRM therapy section includes a pulse generator 539 for use to provide an electrical signal through an electrode to stimulate a heart, and further includes sense circuitry 540 to detect and process sensed cardiac signals. An interface 541 is generally illustrated for use to communicate between the controller 536 and the pulse generator 539 and sense circuitry 540. Three electrodes are illustrated as an example for use to provide CRM therapy. However, the present subject matter is not limited to a particular number of electrode sites. Each electrode may include its own pulse generator and sense circuitry. However, the present subject matter is not so limited. The pulse generating and sensing functions can be multiplexed to function with multiple electrodes.


The NS therapy section 534 includes components, under the control of the controller, to stimulate a baroreceptor and/or sense ANS parameters associated with nerve activity or surrogates of ANS parameters such as blood pressure and respiration. Three interfaces 542 are illustrated for use to provide ANS therapy. However, the present subject matter is not limited to a particular number interfaces, or to any particular stimulating or sensing functions. Pulse generators 543 are used to provide electrical pulses to an electrode for use to stimulate a baroreceptor site. According to various embodiments, the pulse generator includes circuitry to set, and in some embodiments change, the amplitude of the stimulation pulse, the frequency of the stimulation pulse, the burst frequency of the pulse, and the morphology of the pulse such as a square wave, triangle wave, sinusoidal wave, and waves with desired harmonic components to mimic white noise or other signals. Sense circuits 544 are used to detect and process signals from a sensor, such as a sensor of nerve activity, blood pressure, respiration, and the like. The interfaces 542 are generally illustrated for use to communicate between the controller 536 and the pulse generator 543 and sense circuitry 544. Each interface, for example, may be used to control a separate lead. Various embodiments of the NS therapy section only include a pulse generator to stimulate baroreceptors.


According to various embodiments, the lead(s) and the electrode(s) on the leads are physically arranged with respect to the heart in a fashion that enables the electrodes to properly transmit pulses and sense signals from the heart, and with respect to neural targets to stimulate, and in some embodiments sense neural traffic from, the neural targets. Examples of neural targets include both efferent and afferent pathways, such as baroreceptors, nerve trunks and branches such as the vagus nerve, and cardiac fat pads, to provide a desired neural stimulation therapy. As there may be a number of leads and a number of electrodes per lead, the configuration can be programmed to use a particular electrode or electrodes.


The leads of the device include one or more leads to provide CRM therapy, such as atrial pacing, right and/or left ventricular pacing, and/or defibrillation. The device also contains at least on neural stimulation lead which is placed in an appropriate location. Some embodiments perform neural stimulation and CRM therapy using the same lead. Examples of neural stimulation leads include: an expandable stimulation lead placed in the pulmonary artery in proximity of a high concentration of baroreceptors; an intravascularly-fed lead placed proximate to a cardiac fat pad to transvascularly stimulate the fat pad; an epicardial lead with an electrode placed in or proximate to the fat pad; a cuff electrode placed around the aortic, carotid, or vagus nerve; and an intravascularly-fed lead placed to transvascularly stimulate the aortic, carotid or vagus nerve. Other lead placements to stimulate other neural targets may be used.


The controller controls delivery of the electrical pulses using a plurality of parameters for at least one programmed electrical therapy of a first electrical therapy type. The controller is adapted to determine when a therapy of a second electrical therapy type is applied, which can be sensed or other communicated via an alert signal. The controller provides electrical therapy for the first electrical therapy type using a first set of parameters when the therapy of the second electrical therapy type is present to affect the at least one programmed electrical therapy for the first electrical therapy type, and provides electrical therapy using a second set of parameters when the therapy of the second electrical therapy type is not present.


In some embodiments, the first electrical therapy type is a CRM type of therapy, and the second electrical therapy is a neural stimulation type of therapy. There are a number of therapies of a CRM type. Examples include ventricular defibrillation, atrial defibrillation, pacing such as bradycardia and tachycardia pacing, and cardiac rhythm management therapy. In some embodiments, the second electrical therapy type is a neural stimulation (NS) type of therapy. There are a number of therapies of an NS type. Examples include anti-hypertension therapy, therapy for a myocardial infarction, and stimulation to selectively control cardiac conduction and contractility. In other embodiments, the first electrical therapy type is an NS type and the second electrical therapy type is a CRM type.


A plurality of parameters are used by algorithms performed by the controller to deliver the desired therapy. Often, these parameters are adjustable. A programmer, for example, is able to adjust parameters in an IMD. The present subject matter organizes the parameters into at least two sets for a given therapy of the first type. The parameter set used depends on whether the second therapy type is present. The different parameter sets can represent a different value for at least one of the parameters, or can represent at least one different parameter. The different parameter sets can represent different pacing modes, such as atrial pacing (AOO, AAI), ventricular pacing (VVI, VOO), and or dual chamber pacing (DDI, DDD, VDD), for example. Thus, changing the parameter set can change the pacing mode. Additionally, changing the parameter set can change values for parameters for a particular pacing mode, such as base rate, upper rate, AV interval, ventricular refractory and ventricular blanking in a DDD pacing mode.


In some embodiments, the first electrical therapy type is a NS type of therapy, and the second electrical therapy is a CRM type of therapy. Examples of parameters for neural stimulation include parameters that control location of the neural target, and that control amplitude, frequency, burst timing (such as burst frequency and burst duration), and morphology.



FIG. 6 illustrates a system 645 including a programmer 646, an implantable neural stimulator (NS) device 647 and an implantable cardiac rhythm management (CRM) device 648, according to various embodiments of the present subject matter. Various aspects involve a method for communicating between an NS device and a CRM device or other cardiac stimulator. This communication allows one of the devices 647 or 648 to deliver more appropriate therapy (i.e. more appropriate NS therapy or CRM therapy) based on data and/or communication signals received from the other device. Some embodiments provide on-demand communications. The illustrated NS device and the CRM device are capable of wirelessly communicating with each other, and the programmer is capable of wirelessly communicating with at least one of the NS and the CRM devices. For example, various embodiments use telemetry coils to wirelessly communicate data and instructions to each other. In other embodiments, communication of data and/or energy is by ultrasonic means. In some embodiments, a lead provides a hardwired communication path between the two devices. An example of a CRM device is illustrated in FIGS. 3 and 4.



FIG. 7 illustrates an implantable neural stimulator (NS) device 749 such as can be incorporated as the IMD 101 in the system 100 of FIG. 1 or as the neural stimulator 647 in the system 645 of FIG. 6, according to various embodiments of the present subject matter. The illustrated neural stimulator 749 includes controller circuitry 750 connected to a memory 751, a sensor 752, a neural stimulation circuitry 753, and a transceiver 754. An electrode is connected to the stimulator circuitry 753. The memory includes instructions or algorithms operated on by the controller and further includes parameters for use in the algorithms to provide the desired neural stimulation therapy. Some embodiments use the sensor, such as a neural sensor or other physiologic sensor like a heart rate sensor, to provide feedback for the neural stimulation. The stimulator circuitry is adapted to adjust parameters of the neural stimulation signal transmitted to the electrode. According to various embodiments, one or more of the amplitude, the frequency, the morphology and the burst timing (frequency and duration of bursts) are capable of being adjusted. The parameters in the memory are organized into parameter sets to selectively change the neural stimulation, such as by adjusting one or more of the parameters for the neural stimulation signal, depending on whether another therapy type is present.



FIG. 8 illustrates a device, according to various embodiments of the present subject matter, such as the IMD illustrated in FIG. 1, for example. The illustrated device 855 is adapted to provide a first type of therapy, and includes a controller 856 connected to stimulator circuitry 857 to provide therapy. At least one port 858 is connected to the stimulator circuitry 857. The port(s) 858 are adapted to connect with at least one lead 859, with each lead including at least one electrode. The lead(s) and electrode(s) are positioned to provide a desired therapy. Each port provides a communication channel to an electrode.


The controller is adapted to receive an indicator of the presence of a second type of therapy 860. The controller is adapted to provide at least one therapy of the first therapy type 861, and is able to operate in two modes. The controller enters one therapy mode 862 which uses a first parameter set to provide the therapy of the first type when the second type of therapy is not present. The controller enters another therapy mode 863 which uses a second parameter set to provide the therapy of the first type when the second type of therapy is present. Thus, even if the therapy of the second type is intermittent in nature, the device is able to continue to deliver the first type of therapy.



FIG. 9 illustrates a device, according to various embodiments of the present subject matter, such as the IMD illustrated in FIG. 1, for example. The illustrated device 955 includes a header section 965 and a pulse generator section 964. The pulse generator section includes the processing circuitry, and the header provides a physical interface to receive leads 959 and further provides electrical interfaces via ports to provide communication channels to each lead electrode.


The illustrated device 955 is adapted to provide a first type of therapy, and includes a controller 956 connected to stimulator circuitry 957 to provide therapy. At least one port 958 is connected to the stimulator circuitry 957 via switches 966. Sensor circuitry 967 is also connected to the at least one port 958 via the switches 966. The switches are used to allow the same communication channel to be used for both stimulation and sensing. The sensor circuitry 967 is connected to the controller 956.


The device 955 further includes memory 968, which includes instructions and a plurality of adjustable parameters to control the therapy. As illustrated, the parameters are organized into two parameter sets 969 and 970. The controller receives an indicator of the presence of a second type of therapy, such as a detected therapy via the sensor circuitry 967 and/or a communicated signal via transceiver 971. The controller is adapted to provide at least one therapy of the first therapy type 961, and is able to operate in two modes. The controller enters one therapy mode 962 which uses a first parameter set 969 to provide the therapy of the first type when the second type of therapy is not present. The controller enters another therapy mode 963 which uses a second parameter set 970 to provide the therapy of the first type when the second type of therapy is present.


The present subject matter is capable of automatically adjusting parameters used to deliver therapy of a first type in response to whether therapy of a second type is present. The present subject matter is also capable of automatically adjusting parameters used to deliver therapy of the first type based on the intensity of the therapy of the second type. Such embodiments can be based on one or more threshold intensities that define different intensity levels. Each intensity level can be associated with a parameter set. Some embodiments adjust the parameters proportionally to the intensity of the second therapy. The parameter adjustments can be linearly or nonlinearly related to the intensity change for the therapy of the second type. The parameter set used for the therapy of the first therapy type can be based solely on whether the therapy of the second therapy type is present, can be based solely on an intensity of the therapy of the second therapy type, and can be based on a combination of whether the therapy of the second therapy type is present and the intensity of the therapy of the second therapy type.



FIG. 10 illustrates a method, according to various embodiments. At 1072, a therapy (e.g. bradycardia support pacing) of a first type (e.g. CRM therapy) is delivered. At 1073, it is determined whether a therapy (e.g. neural stimulation of cardiac fat pad) of a second therapy type (neural stimulation therapy) is present and/or the intensity of the therapy of the second type is determined. At 1074, the delivery of therapy of the first therapy type is controlled based on a plurality of parameters organized into at least two sets and based on whether the therapy of the second type is present and/or the intensity of the therapy of the second type.



FIG. 11A illustrates a method for controlling delivery of therapy of the first type (e.g. CRM therapy) based on a plurality of parameters organized into at least two sets and based on whether the therapy of the second type (e.g. neural stimulation therapy) is present, according to various embodiments. At 1173, it is determined whether the therapy of the second type is present. If the second type of therapy is not present, the process proceeds to 1174 where the therapy of the first type is delivered using a first parameter set 1174. If the second type of therapy is present, the process proceeds to 1175 where the therapy of the first type is delivered using a second parameter set 1175.



FIG. 11B illustrates a method for controlling delivery of therapy of the first type (e.g. CRM therapy) based the intensity of the therapy of the second type (e.g. neural stimulation therapy), according to various embodiments. At 1176, the intensity level of the therapy of the second type is determined. The determination of the intensity level can be use a few distinct levels separated by threshold values, such as a high and low intensity, or can more precisely quantify the intensity level throughout the continuum from the lowest to highest intensities. At 1177, therapy of the first type is delivered using a parameter set selected based on the intensity level determined at 1176.



FIG. 11C illustrates a method for controlling delivery of therapy of the first type (e.g. CRM therapy) based on whether the therapy of the second type (e.g. neural stimulation therapy) is present and on the intensity of the therapy of the second type, according to various embodiments. At 1178, it is determined whether therapy of the second type is present. If the therapy of the second type is not present, the process proceeds to 1179, where therapy of the first type is delivered using a parameter set selected for situations without the therapy of the second type. If the therapy of the second type is present, the process proceeds to 1180 where the intensity level of the therapy of the second type is determined, and to 1181 where the therapy of the first types is delivered using a parameter set selected based on the intensity level.



FIGS. 12A, 12B and 12C illustrate plurality of parameters, and further illustrate the first and second sets of parameters, according to various embodiments. FIG. 12A illustrates a first set and a second set in which the sets are exclusive of each other. That is, the sets are defined and organized to be mutually exclusive such that each set includes distinct parameters with respect to the other set. FIG. 12B illustrates a first set and a second set that are at least partially inclusive, being defined and organized to share at least some parameters. FIG. 12C illustrates a first set that is a subset of the second set. In addition to the illustrated relationships between the first and second sets, some embodiments may include sets with the same parameters, where the differences between the parameter sets are provided by different adjustable or programmable values of the parameters.


In some embodiments, all of the adjustable parameters in each parameter set are independently programmable. In some embodiments, the adjustable parameters in one parameter set is programmable, and the adjustable parameters in the other parameter set are automatically adjusted as a function of the values for the parameters in the first parameter set.


One of ordinary skill in the art will understand that, the modules and other circuitry shown and described herein can be implemented using software, hardware, and combinations of software and hardware. As such, the illustrated modules and circuitry are intended to encompass software implementations, hardware implementations, and software and hardware implementations.


The methods illustrated in this disclosure are not intended to be exclusive of other methods within the scope of the present subject matter. Those of ordinary skill in the art will understand, upon reading and comprehending this disclosure, other methods within the scope of the present subject matter. The above-identified embodiments, and portions of the illustrated embodiments, are not necessarily mutually exclusive. These embodiments, or portions thereof, can be combined. For example, various embodiments combine two or more of the illustrated processes. Two or more sensed parameters can be combined into a composite parameter used to provide a desired CRM therapy. In various embodiments, the methods provided above are implemented as a computer data signal embodied in a carrier wave or propagated signal, that represents a sequence of instructions which, when executed by a processor cause the processor to perform the respective method. In various embodiments, methods provided above are implemented as a set of instructions contained on a computer-accessible medium capable of directing a processor to perform the respective method. In various embodiments, the medium is a magnetic medium, an electronic medium, or an optical medium.


Although specific embodiments have been illustrated and described herein, it will be appreciated by those of ordinary skill in the art that any arrangement which is calculated to achieve the same purpose may be substituted for the specific embodiment shown. This application is intended to cover adaptations or variations of the present subject matter. It is to be understood that the above description is intended to be illustrative, and not restrictive. Combinations of the above embodiments as well as combinations of portions of the above embodiments in other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the present subject matter should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims
  • 1. A system to deliver an electrical therapy to a patient to whom another electrical therapy is also delivered, comprising: an electrical stimulator to deliver electrical pulses to the patient for the electrical therapy; anda controller connected to the electrical stimulator and configured to operate in a first mode to control delivery of the electrical pulses for the electrical therapy when the other electrical therapy is not delivered and to operate in a second mode in response to delivery of the other electrical therapy, wherein operating in the first mode includes performing a first sensing operation and operating in the second mode includes performing a second sensing operation different from the first sensing operation.
  • 2. The system of claim 1, wherein operating in the first mode includes operating in a first pacing mode, and operating in the second mode includes operating in a second pacing mode.
  • 3. The system of claim 1, wherein performing a first sensing operation or performing a second sensing operation includes providing feedback, the controller configured to use the feedback to the control the electrical therapy.
  • 4. The system of claim 1, wherein the controller is configured to trigger the electrical pulses for the electrical therapy in response to sensed events sensed in at least one of the first sensing operation or the second sensing operation.
  • 5. The system of claim 1, wherein the controller is configured to inhibit the electrical pulses for the electrical therapy in response to sensed events sensed in at least one of the first sensing operation or the second sensing operation.
  • 6. The system of claim 1, further comprising a sense circuit operably connected to the controller and configured to sense cardiac activity.
  • 7. The system of claim 1, further comprising a sense circuit operably connected to the controller and configured to sense heart rate.
  • 8. The system of claim 1, further comprising a sense circuit operably connected to the controller and configured to sense blood pressure.
  • 9. The system of claim 1, further comprising a sense circuit operably connected to the controller and configured to sense respiration.
  • 10. The system of claim 1, wherein the electrical stimulator includes a neural stimulator.
  • 11. The system of claim 1, wherein the electrical stimulator includes a cardiac rhythm management device.
  • 12. The system of claim 1, wherein the controller is configured to account for a change in a presence of the other electrical therapy, or is configured to account for a change in an intensity of the other electrical therapy, or is configured to account for both a change in a presence and a change in an intensity of the other electrical therapy.
  • 13. The system of claim 1, wherein performing a first sensing operation or performing a second sensing operation includes interpreting sensed signals.
  • 14. The system of claim 1, further comprising a sensing amplifier operably connected to the controller, the sensing amplifier having an adjustable gain.
  • 15. The system of claim 1, further comprising a sensing amplifier operably connected to the controller, the sensing amplifier having an adjustable threshold.
  • 16. A system to deliver an electrical therapy and another electrical therapy to a patient, comprising: a first implantable medical device configured to deliver the electrical therapy to the patient;a second device configured to intermittently deliver the other electrical therapy to the patient;the first implantable medical device including: an electrical stimulator to deliver electrical pulses to the patient for the electrical therapy;a sensor, anda controller operably connected to the sensor, the controller operably connected to the electrical stimulator and configured to operate in a first mode to control delivery of the electrical pulses for the electrical therapy when the other electrical therapy is not delivered and to operate in a second mode in response to delivery of the other electrical therapy, wherein operating in the first mode includes performing a first sensing operation and operating in the second mode includes performing a second sensing operation different from the first sensing operation.
  • 17. The system of claim 16, wherein the first implantable medical device includes a neural stimulator and the second implantable medical device includes a myocardial stimulator.
  • 18. The system of claim 16, wherein the first implantable medical device includes a myocardial stimulator and the second implantable medical device includes a neural stimulator.
  • 19. The system of claim 16, wherein the first medical device includes a sensor operably connected to the controller, the sensor including a heart rate sensor, a blood pressure sensor, or a respiration sensor.
  • 20. The system of claim 16, wherein the sensor includes an adjustable gain or an adjustable threshold.
CLAIM OF PRIORITY

This application is a continuation of U.S. application Ser. No. 13/954,342, filed Jul. 30, 2013, now issued as U.S. Pat. No. 8,805,494, which is a continuation of U.S. application Ser. No. 13/397,115, filed Feb. 15, 2012, now U.S. Pat. No. 8,504,149, which is a divisional of U.S. application Ser. No. 12/148,843, filed Apr. 23, 2008, now U.S. Pat. No. 8,131,359, which is a divisional of U.S. Application Ser. No. 11/125,503, filed May 10, 2005, now U.S. Pat. No. 7,493,161, the specifications of which are herein incorporated by reference.

US Referenced Citations (275)
Number Name Date Kind
3421511 Schwartz et al. Jan 1969 A
3650277 Sjostrand et al. Mar 1972 A
4201219 Bozal Gonzalez May 1980 A
4592359 Galbraith Jun 1986 A
4702254 Zabara Oct 1987 A
4763646 Lekholm Aug 1988 A
4770177 Schroeppel Sep 1988 A
4791931 Slate Dec 1988 A
4880005 Pless et al. Nov 1989 A
4936304 Kresh et al. Jun 1990 A
4960129 dePaola et al. Oct 1990 A
5014698 Cohen May 1991 A
5052388 Sivula et al. Oct 1991 A
5111815 Mower May 1992 A
5199428 Obel et al. Apr 1993 A
5203326 Collins Apr 1993 A
5224475 Berg et al. Jul 1993 A
5243980 Mehra Sep 1993 A
5318592 Schaldach Jun 1994 A
5330507 Schwartz Jul 1994 A
5334221 Bardy Aug 1994 A
5356425 Bardy et al. Oct 1994 A
5403351 Saksena Apr 1995 A
5411531 Hill et al. May 1995 A
5437285 Verrier et al. Aug 1995 A
5507784 Hill et al. Apr 1996 A
5522854 Ideker et al. Jun 1996 A
5540730 Terry, Jr. et al. Jul 1996 A
5562711 Yerich et al. Oct 1996 A
5578061 Stroetmann et al. Nov 1996 A
5626621 Skoglund et al. May 1997 A
5658318 Stroetmann et al. Aug 1997 A
5662689 Elsberry et al. Sep 1997 A
5690681 Geddes et al. Nov 1997 A
5700282 Zabara Dec 1997 A
5731848 Patel et al. Mar 1998 A
5792187 Adams Aug 1998 A
5817131 Elsberry et al. Oct 1998 A
5893881 Elsberry et al. Apr 1999 A
5916239 Geddes et al. Jun 1999 A
5928272 Adkins et al. Jul 1999 A
6006134 Hill et al. Dec 1999 A
6018682 Rise Jan 2000 A
6058331 King May 2000 A
6073048 Kieval et al. Jun 2000 A
6104956 Naritoku et al. Aug 2000 A
6119043 Hsu et al. Sep 2000 A
6134470 Hartlaub Oct 2000 A
6178349 Kieval Jan 2001 B1
6205359 Boveja Mar 2001 B1
6240314 Plicchi et al. May 2001 B1
6292695 Webster, Jr. et al. Sep 2001 B1
6304772 Taha et al. Oct 2001 B1
6337997 Rise Jan 2002 B1
6341236 Osorio et al. Jan 2002 B1
6349233 Adams Feb 2002 B1
6356788 Boveja Mar 2002 B2
6363278 Stahmann et al. Mar 2002 B1
6371922 Baumann et al. Apr 2002 B1
6400982 Sweeney et al. Jun 2002 B2
6415183 Scheiner et al. Jul 2002 B1
6421557 Meyer Jul 2002 B1
6438423 Rezai et al. Aug 2002 B1
6449507 Hill et al. Sep 2002 B1
6466822 Pless Oct 2002 B1
6473644 Terry, Jr. et al. Oct 2002 B1
6477404 Yonce et al. Nov 2002 B1
6477418 Plicchi et al. Nov 2002 B2
6487446 Hill et al. Nov 2002 B1
6487450 Chen Nov 2002 B1
6493585 Plicchi et al. Dec 2002 B2
6511500 Rahme Jan 2003 B1
6522926 Kieval et al. Feb 2003 B1
6532388 Hill et al. Mar 2003 B1
6542774 Hill et al. Apr 2003 B2
6564096 Mest May 2003 B2
6587727 Osorio et al. Jul 2003 B2
6597954 Fischell et al. Jul 2003 B1
6600954 Cohen et al. Jul 2003 B2
6610713 Tracey Aug 2003 B2
6611713 Schauerte Aug 2003 B2
6622041 Terry, Jr. et al. Sep 2003 B2
6628987 Hill et al. Sep 2003 B1
6658287 Litt et al. Dec 2003 B1
6668191 Boveja Dec 2003 B1
6671556 Osorio et al. Dec 2003 B2
6684105 Cohen et al. Jan 2004 B2
6690974 Archer et al. Feb 2004 B2
6735471 Hill et al. May 2004 B2
6788975 Whitehurst et al. Sep 2004 B1
6810285 Pless et al. Oct 2004 B2
6920357 Osorio et al. Jul 2005 B2
6922585 Zhou et al. Jul 2005 B2
6928324 Park et al. Aug 2005 B2
6934583 Weinberg et al. Aug 2005 B2
6937896 Kroll Aug 2005 B1
6965797 Pastore et al. Nov 2005 B2
7025730 Cho et al. Apr 2006 B2
7039466 Harrison et al. May 2006 B1
7069070 Carlson et al. Jun 2006 B2
7123961 Kroll et al. Oct 2006 B1
7123967 Weinberg Oct 2006 B2
7139607 Shelchuk Nov 2006 B1
7155278 King et al. Dec 2006 B2
7158832 Kieval et al. Jan 2007 B2
7260431 Libbus et al. Aug 2007 B2
7277761 Shelchuk Oct 2007 B2
7299086 McCabe et al. Nov 2007 B2
7493161 Libbus et al. Feb 2009 B2
7542794 Zhang et al. Jun 2009 B1
7542800 Libbus et al. Jun 2009 B2
7565195 Kroll et al. Jul 2009 B1
7570999 Libbus et al. Aug 2009 B2
7587238 Moffitt et al. Sep 2009 B2
7657312 Pastore et al. Feb 2010 B2
7660628 Libbus et al. Feb 2010 B2
7665195 Vazquez-Perez Feb 2010 B1
7769450 Libbus et al. Aug 2010 B2
7840271 Kieval et al. Nov 2010 B2
7873413 McCabe et al. Jan 2011 B2
8131359 Libbus et al. Mar 2012 B2
20010003799 Boveja Jun 2001 A1
20010016759 Kramer et al. Aug 2001 A1
20020016344 Tracey Feb 2002 A1
20020016550 Sweeney et al. Feb 2002 A1
20020026221 Hill et al. Feb 2002 A1
20020026222 Schauerte et al. Feb 2002 A1
20020035378 Bardy et al. Mar 2002 A1
20020058877 Baumann et al. May 2002 A1
20020072776 Osorio et al. Jun 2002 A1
20020077670 Archer et al. Jun 2002 A1
20020082661 Plicchi et al. Jun 2002 A1
20020091415 Lovett et al. Jul 2002 A1
20020107553 Hill et al. Aug 2002 A1
20020116030 Rezai Aug 2002 A1
20020120304 Mest Aug 2002 A1
20020123769 Panken et al. Sep 2002 A1
20020143369 Hill et al. Oct 2002 A1
20020161410 Kramer et al. Oct 2002 A1
20020165586 Hill et al. Nov 2002 A1
20020169485 Pless et al. Nov 2002 A1
20020183237 Puskas Dec 2002 A1
20020188325 Hill et al. Dec 2002 A1
20020188326 Zheng et al. Dec 2002 A1
20020198570 Puskas Dec 2002 A1
20030004549 Hill et al. Jan 2003 A1
20030023279 Spinelli et al. Jan 2003 A1
20030040774 Terry, Jr. et al. Feb 2003 A1
20030045909 Gross et al. Mar 2003 A1
20030045914 Cohen et al. Mar 2003 A1
20030060848 Kieval et al. Mar 2003 A1
20030060857 Perrson et al. Mar 2003 A1
20030060858 Kieval et al. Mar 2003 A1
20030074039 Puskas Apr 2003 A1
20030078623 Weinberg et al. Apr 2003 A1
20030078629 Chen Apr 2003 A1
20030100924 Foreman et al. May 2003 A1
20030105493 Salo Jun 2003 A1
20030149450 Mayberg Aug 2003 A1
20030153953 Park et al. Aug 2003 A1
20030181951 Cates Sep 2003 A1
20030181958 Dobak, III Sep 2003 A1
20030195578 Perron et al. Oct 2003 A1
20030212440 Boveja Nov 2003 A1
20030212445 Weinberg Nov 2003 A1
20030216792 Levin et al. Nov 2003 A1
20030229380 Adams et al. Dec 2003 A1
20030236558 Whitehurst et al. Dec 2003 A1
20040002635 Hargrove et al. Jan 2004 A1
20040010303 Bolea et al. Jan 2004 A1
20040015204 Whitehurst et al. Jan 2004 A1
20040044377 Larsson Mar 2004 A1
20040049120 Cao et al. Mar 2004 A1
20040054381 Pastore et al. Mar 2004 A1
20040082980 Mouine et al. Apr 2004 A1
20040088009 Degroot May 2004 A1
20040088015 Casavant et al. May 2004 A1
20040102820 Mouine et al. May 2004 A1
20040116970 Girouard et al. Jun 2004 A1
20040133248 Frei et al. Jul 2004 A1
20040138721 Osorio et al. Jul 2004 A1
20040138724 Sieracki et al. Jul 2004 A1
20040158295 Dyjach et al. Aug 2004 A1
20040162594 King Aug 2004 A1
20040172074 Yoshihito Sep 2004 A1
20040172075 Shafer et al. Sep 2004 A1
20040172089 Whitehurst et al. Sep 2004 A1
20040172094 Cohen et al. Sep 2004 A1
20040193231 David et al. Sep 2004 A1
20040199210 Shelchuk Oct 2004 A1
20040210261 King et al. Oct 2004 A1
20040215289 Fukui Oct 2004 A1
20040220621 Zhou et al. Nov 2004 A1
20040254612 Ezra et al. Dec 2004 A1
20050010263 Schauerte Jan 2005 A1
20050015129 Mische Jan 2005 A1
20050021092 Yun et al. Jan 2005 A1
20050027321 Ferek-Petric Feb 2005 A1
20050059897 Snell et al. Mar 2005 A1
20050060001 Singhal et al. Mar 2005 A1
20050065554 KenKnight et al. Mar 2005 A1
20050065555 Er Mar 2005 A1
20050065575 Dobak Mar 2005 A1
20050075690 Toy et al. Apr 2005 A1
20050075701 Shafer Apr 2005 A1
20050085864 Schulman et al. Apr 2005 A1
20050096705 Pastore et al. May 2005 A1
20050107844 Van Den Honert et al. May 2005 A1
20050143779 Libbus Jun 2005 A1
20050143785 Libbus Jun 2005 A1
20050143787 Boveja et al. Jun 2005 A1
20050148896 Siejko et al. Jul 2005 A1
20050149126 Libbus Jul 2005 A1
20050149127 Libbus Jul 2005 A1
20050149128 Heil et al. Jul 2005 A1
20050149129 Libbus et al. Jul 2005 A1
20050149130 Libbus Jul 2005 A1
20050149131 Libbus et al. Jul 2005 A1
20050149132 Libbus Jul 2005 A1
20050149133 Libbus et al. Jul 2005 A1
20050149143 Libbus et al. Jul 2005 A1
20050149148 King Jul 2005 A1
20050149155 Scheiner et al. Jul 2005 A1
20050149156 Libbus et al. Jul 2005 A1
20050154418 Kieval et al. Jul 2005 A1
20050182288 Zabara Aug 2005 A1
20050182453 Whitehurst et al. Aug 2005 A1
20050187584 Denker et al. Aug 2005 A1
20050197600 Schuler et al. Sep 2005 A1
20050197674 McCabe et al. Sep 2005 A1
20050251216 Hill et al. Nov 2005 A1
20050261741 Libbus et al. Nov 2005 A1
20060004417 Rossing et al. Jan 2006 A1
20060020297 Gerber et al. Jan 2006 A1
20060052831 Fukui Mar 2006 A1
20060079945 Libbus Apr 2006 A1
20060095080 Libbus et al. May 2006 A1
20060106429 Libbus et al. May 2006 A1
20060116737 Libbus Jun 2006 A1
20060122675 Libbus et al. Jun 2006 A1
20060167497 Armstrong et al. Jul 2006 A1
20060195038 Carlson et al. Aug 2006 A1
20060206153 Libbus et al. Sep 2006 A1
20060206154 Moffitt et al. Sep 2006 A1
20060206158 Wu et al. Sep 2006 A1
20060206159 Moffitt et al. Sep 2006 A1
20060217772 Libbus et al. Sep 2006 A1
20060224188 Libbus et al. Oct 2006 A1
20060224202 Moffitt et al. Oct 2006 A1
20060229677 Moffitt et al. Oct 2006 A1
20060241699 Libbus et al. Oct 2006 A1
20060241725 Libbus et al. Oct 2006 A1
20060253156 Pastore et al. Nov 2006 A1
20060259083 Libbus et al. Nov 2006 A1
20060271118 Libbus et al. Nov 2006 A1
20070021790 Kieval et al. Jan 2007 A1
20070021799 Kieval et al. Jan 2007 A1
20070038261 Kieval et al. Feb 2007 A1
20070142864 Libbus et al. Jun 2007 A1
20070142871 Libbus et al. Jun 2007 A1
20080015648 Libbus et al. Jan 2008 A1
20080021504 McCabe et al. Jan 2008 A1
20080167693 Kieval et al. Jul 2008 A1
20080167694 Bolea et al. Jul 2008 A1
20080200959 Libbus et al. Aug 2008 A1
20080228238 Libbus Sep 2008 A1
20090018596 Kieval Jan 2009 A1
20090030484 Chambers Jan 2009 A1
20090228060 Libbus et al. Sep 2009 A1
20100121399 McCabe et al. May 2010 A1
20100285196 Moore et al. Nov 2010 A1
20110106199 Mccabe et al. May 2011 A1
20110137360 Ternes et al. Jun 2011 A1
20120150250 Libbus et al. Jun 2012 A1
20130317561 Libbus et al. Nov 2013 A1
Foreign Referenced Citations (55)
Number Date Country
0547734 Jun 1993 EP
0688578 Dec 1995 EP
0709112 May 1996 EP
0721786 Jul 1996 EP
1304135 Apr 2003 EP
1421973 May 2004 EP
1421973 May 2004 EP
1426078 Jun 2004 EP
1486232 Dec 2004 EP
1541193 Jun 2005 EP
8-52121 Feb 1996 JP
2004173791 Jun 2004 JP
2004351122 Dec 2004 JP
2005500863 Jan 2005 JP
WO-9216257 Oct 1992 WO
WO-9713550 Apr 1997 WO
WO-9904329 Jan 1999 WO
WO-9965561 Dec 1999 WO
WO-0004950 Feb 2000 WO
WO-0226318 Apr 2002 WO
WO-0234327 May 2002 WO
WO-02085448 Oct 2002 WO
WO-02087694 Nov 2002 WO
WO-03011388 Feb 2003 WO
WO-03018108 Mar 2003 WO
WO-03020364 Mar 2003 WO
WO-03041559 May 2003 WO
WO-03076008 Sep 2003 WO
WO-03082080 Oct 2003 WO
WO-03099373 Dec 2003 WO
WO-03099377 Dec 2003 WO
WO-2004012814 Feb 2004 WO
WO-2004033036 Apr 2004 WO
WO-2004084990 Oct 2004 WO
WO-2004084993 Oct 2004 WO
WO-2004103455 Dec 2004 WO
WO-2004105870 Dec 2004 WO
WO-2004110549 Dec 2004 WO
WO-2004110550 Dec 2004 WO
WO-2005018739 Mar 2005 WO
WO-2005042091 May 2005 WO
WO-2006055436 May 2005 WO
WO-2005063332 Jul 2005 WO
WO-2005065771 Jul 2005 WO
WO-2005113066 Dec 2005 WO
WO-2006031331 Mar 2006 WO
WO-2006044025 Apr 2006 WO
WO-2006107675 Oct 2006 WO
WO-2006121929 Nov 2006 WO
WO-2006127248 Nov 2006 WO
WO-2007078410 Jul 2007 WO
WO-2008063396 May 2008 WO
WO-2008144354 Nov 2008 WO
WO-2011071896 Jun 2011 WO
WO-2011088222 Jul 2011 WO
Non-Patent Literature Citations (187)
Entry
“U.S. Appl. No. 11/125,503, Notice of Allowance mailed Jan. 4, 2008”, 8 pgs.
“U.S. Appl. No. 10/746,846, Final Office Action mailed Jan. 23, 2008”, 18 pgs.
“U.S. Appl. No. 10/746,846, Final Office Action mailed Feb. 12, 2007”, 17 pgs.
“U.S. Appl. No. 10/746,846, Non Final Office Action mailed Apr. 26, 2007”, 18 pgs.
“U.S. Appl. No. 10/746,846, Non Final Office Action mailed Jul. 25, 2006”, 15 pgs.
“U.S. Appl. No. 10/746,846, Response filed Apr. 17, 2007 to Final Office Action mailed Feb. 12, 2007”, 16 pgs.
“U.S. Appl. No. 10/746,846, Response filed Jul. 7, 2006 to Restriction Requirement mailed Jun. 9, 2006”, 13 pgs.
“U.S. Appl. No. 10/746,846, Response filed Oct. 26, 2007 to Non Final Office Action mailed Apr. 26, 2007”, 11 pgs.
“U.S. Appl. No. 10/746,846, Response filed Nov. 9, 2006 to Non Final Office Action mailed Jul. 25, 2006”, 17 pgs.
“U.S. Appl. No. 10/746,846, Restriction Requirement mailed Jun. 9, 2006”, 7 pgs.
“U.S. Appl. No. 10/962,845, Appeal Brief mailed Sep. 26, 2007”, 33 pgs.
“U.S. Appl. No. 10/962,845, Final Office Action mailed Jan. 26, 2007”, 7 pgs.
“U.S. Appl. No. 10/962,845, Non Final Office Action mailed May 12, 2006”, 10 pgs.
“U.S. Appl. No. 10/962,845, Preliminary Amendment filed Apr. 25, 2005”, 11 pgs.
“U.S. Appl. No. 10/962,845, Response filed Oct. 12, 2006 to Non Final Office Action mailed May 12, 2006”, 14 pgs.
“U.S. Appl. No. 11/099,141, Final Office Action mailed Oct. 22, 2007”, 9 pgs.
“U.S. Appl. No. 11/099,141, Final Office Action mailed Nov. 7, 2008”, 8 pgs.
“U.S. Appl. No. 11/099,141, Non-Final Office Action mailed May 6, 2008”, 11 pgs.
“U.S. Appl. No. 11/099,141, Non-Final Office Action mailed May 18, 2007”, 8 pgs.
“U.S. Appl. No. 11/099,141, Notice of Allowance mailed Jan. 28, 2009”, 4 pgs.
“U.S. Appl. No. 11/099,141, Response filed Jan. 6, 2009 to Final Final Office Action mailed Nov. 7, 2008”, 9 pgs.
“U.S. Appl. No. 11/099,141, Response filed Feb. 19, 2008 to Final Office Action mailed Oct. 22, 2007”, 13 pgs.
“U.S. Appl. No. 11/099,141, Response filed Apr. 5, 2007 to Restriction Requirement mailed Mar. 6, 2007”, 11 pgs.
“U.S. Appl. No. 11/099,141, Response filed Aug. 4, 2008 to Non Final Office Action mailed May 6, 2008”, 10 pgs.
“U.S. Appl. No. 11/099,141, Response filed Aug. 20, 2007 to Non Final Office Action mailed May 18, 2007”, 11 pgs.
“U.S. Appl. No. 11/099,141, Restriction Requirement mailed Mar. 6, 2007”, 6 pgs.
“U.S. Appl. No. 11/125,503, Examiner Interview Summary mailed Oct. 18, 2007”, 4 pgs.
“U.S. Appl. No. 11/125,503, Non-Final Office Action mailed Jun. 28, 2007”, 8 pgs.
“U.S. Appl. No. 11/125,503, Notice of Allowance mailed Mar. 8, 2007”, 8 pgs.
“U.S. Appl. No. 11/125,503, Response filed Oct. 29, 2007 to Non Final Office Action mailed Jun. 28, 2007”, 21 pgs.
“U.S. Appl. No. 11/137, 038, Appeal Brief mailed Jan. 18, 2010”, 35 pgs.
“U.S. Appl. No. 11/137,038, Final Office Action mailed Aug. 14, 2009”, 10 pgs.
“U.S. Appl. No. 11/137,038, Final Office Action mailed Aug. 29, 2008”, FOAR, 10 pgs.
“U.S. Appl. No. 11/137,038, Non-Final Office Action mailed Feb. 5, 2008”, OARN, 8 pgs.
“U.S. Appl. No. 11/312,178, Non-Final Office Action mailed May 14, 2008”, 6 pgs.
“U.S. Appl. No. 11/312,178, Notice of Allowance mailed Apr. 3, 2009”, 6 pgs.
“U.S. Appl. No. 11/312,178, Notice of Allowance mailed Nov. 14, 2008”, 6 pgs.
“U.S. Appl. No. 11/312,178, Preliminary Amendment filed Mar. 14, 2006”, 7 pgs.
“U.S. Appl. No. 11/312,178, Response filed Aug. 14, 2008 to Non Final Office Action mailed May 14, 2008”, 14 pgs.
“U.S. Appl. No. 11/459,481 Notice of Allowance mailed Sep. 20, 2010”, 7 pgs.
“U.S. Appl. No. 11/459,481 Restriction Requirement mailed Jan. 29, 2010”, 6 pgs.
“U.S. Appl. No. 11/459,481, Final Office Action mailed May 17, 2010”, 11 pgs.
“U.S. Appl. No. 11/459,481, Non-Final Office Action mailed May 28, 2009”, 10 pgs.
“U.S. Appl. No. 11/459,481, Response filed Jan. 29, 2009 to Restriction Requirement mailed Dec. 30, 2008”, 10 pgs.
“U.S. Appl. No. 11/459,481, Response filed Feb. 10, 2010 to Restriction Requirement mailed Jan. 29, 2010”, 8 pgs.
“U.S. Appl. No. 11/459,481, Response filed Aug. 17, 2010 to Final Office Action mailed May 17, 2010”, 9 pgs.
“U.S. Appl. No. 11/459,481, Response filed Nov. 25, 2009 to Non Final Office Action mailed May 28, 2009”, 14 pgs.
“U.S. Appl. No. 11/459,481, Restriction Requirement mailed Dec. 30, 2008”, 7 pgs.
“U.S. Appl. No. 11/482,635, Preliminary Statement Oct. 31, 2006”, 2 pgs.
“U.S. Appl. No. 11/558,083, Response filed Dec. 22, 2009 to Non-Final Office Action mailed Jun. 26, 2009”, 15 pgs.
“U.S. Appl. No. 11/868,408, Preliminary Amendment filed Oct. 5, 2007”, 2 pgs.
“U.S. Appl. No. 12/148,843, Non Final Office Action mailed May 31, 2011”, 8 pgs.
“U.S. Appl. No. 12/148,843, Notice of Allowance mailed Oct. 27, 2011”, 10 pgs.
“U.S. Appl. No. 12/148,843, Response filed Aug. 30, 2011 to Non Final Office Action mailed May 31, 2011”, 9 pgs.
“U.S. Appl. No. 12/148,843, Response filed Apr. 14, 2011 to Restriction Requirement mailed Mar. 15, 2011”, 10 pgs.
“U.S. Appl. No. 12/148,843, Restriction Requirement mailed Mar. 15, 2011”, 9 pgs.
“U.S. Appl. No. 12/688,575, Response to Restriction Requirement mailed Mar. 30, 2012”, 14 pgs.
“U.S. Appl. No. 12/688,575, Restriction Requirement mailed Mar. 30, 2012”, 26 pgs.
“U.S. Appl. No. 13/397,115 , Response filed Feb. 19, 2013 to Non Final Office Action mailed Nov. 21, 2012”, 13 pgs.
“U.S. Appl. No. 13/397,115, Non Final Office Action mailed Nov. 21, 2012”, 10 pgs.
“U.S. Appl. No. 13/397,115, Notice of Allowance mailed Apr. 3, 2013”, 6 pgs.
“U.S. Appl. No. 13/954,342, Notice of Allowance mailed Apr. 7, 2014”, 8 pgs.
“U.S. Appl. No. 13/954,342, Response filed Feb. 25, 2014 to Non Final Office Action mailed Dec. 10, 2013”, 12 pgs.
“European Application Serial No. 06752356.3, Office Action mailed Apr. 1, 2008”, 6 pgs.
“European Application Serial No. 06752356.3, Response filed Sep. 11, 2008 to Communication mailed Apr. 1, 2008”, 17 pgs.
“European Application Serial No. 06827323.4, Response filed Apr. 24, 2009 to Communication mailed Nov. 12, 2008”, 6 pgs.
“European Application Serial No. 06827323.4, Summons to Attend Oral Proceedings mailed May 19, 2010”, 3 pgs.
“European Application Serial No. 06827323.4, Written Submissions filed Sep. 23, 2010”, 4 pgs.
“International Application Serial No. PCT/US2006/042727, International Search Report and Written Opinion mailed Apr. 23, 2007”, 16 pgs.
“International Application Serial No. PCT/US2006/011446, International Search Report and Written Opinion mailed Aug. 25, 2006”, 14 pgs.
“International Application Serial No. PCT/US2006/017539, International Search Report and Written Opinion mailed Sep. 1, 2006”, 12 pgs.
“International Application Serial No. PCT/US2006/017637, International Search Report and Written Opinion mailed Oct. 20, 2006”.
“International Application Serial No. PCT/US2010/059252, International Search Report mailed Mar. 2, 2011”, 4 pgs.
“International Application Serial No. PCT/US2010/059252, Written Opinion mailed Mar. 2, 2011”, 7 pgs.
“International Application Serial No. PCT/US2011/021154, Search Report mailed Mar. 10, 2011”, 5 pgs.
“International Application Serial No. PCT/US2011/021154, Written Opinion mailed Mar. 10, 2011”, 9 pgs.
“International Search Report and Written Opinion for Application No. PCT/US2006/008314, dated Jul. 6, 2006”, 13 pgs.
“Japanese Application Serial No. 2008-511206, Office Action mailed May 17, 2012”, With English Translation, 7 pgs.
“Japanese Application Serial No. 2008-511206, Office Action mailed Nov. 11, 2011”, With English Translation, With English Translation, 7 pgs.
“Japanese Application Serial No. 2008-511206, Office Action Response filed Mar. 9, 2012”, With English Translation, 12 pgs.
“Japanese Application Serial No. 2008-547225, Office Action mailed Nov. 29, 2011”, W/ English Translation, 4 pgs.
“Japanese Application Serial No. 2008-547225, Response filed Feb. 29, 2012 to Office Action mailed Nov. 29, 2011”, (w/ English Translation of Claims), 16 pgs.
Andersen, H, et al., “Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome”, Lancet, 350(9086), (Oct. 25, 1997), 1210-6.
Benchimol, A, et al., “Cardiac hemodynamics during stimulation of the right atrium, right ventricle, and left ventricle in normal and abnormal hearts”, Circulation, 33(6), (Jun. 1966), 933-44.
Bevan, J A, et al., “Postganglionic sympathetic delay in vascular smooth muscle”, Journal of Pharmacology & Experimental Therapeutics, 152(2), (May 1966), 221-30.
Bevan, J A, et al., “Sympathetic nerve-free vascular muscle”, Journal of Pharmacology & Experimental Therapeutics, 157(1), (Jul. 1967), 117-24.
Bilgutay, A M, et al., “A new concept in the treatment of hypertension utilizing an implantable electronic device: “Baropacer””, Trans Am Soc Artif Intern Organs., 10, (1964), 387-395.
Bilgutay, A M, et al., “Vagal tuning for the control of supraventricular arrhythmias”, Surgical Forum, 16, (1965), 151-3.
Bilgutay, A. M, et al., “Vagal tuning. A new concept in the treatment of supraventricular arrhythmias, angina pectoris, and heart failure”, Journal of Thoracic and Cardiovascular Surgery, 56(1), (Jul. 1968), 71-82.
Borst, C, et al., “Optimal frequency of carotid sinus nerve stimulation in treatment of angina pectoris”, Cardiovascular Research, 8(5), (Sep. 1974), 674-80.
Braunwald, E, et al., “Carotid sinus nerve stimulation in the treatment of angina pectoris and supraventricular tachycardia”, California Medicine, 112(3), (Mar. 1970), 41-50.
Braunwald, E, et al., “Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves”, New England Journal of Medicine, 277(24), (Dec. 14, 1967), 1278-83.
Caparso, Anthony, et al., “System for Neural Control of Respiration”, U.S. Appl. No. 11/151,122, filed Jun. 13, 2005, 28 pgs.
Caparso, Anthony, “System for Selective Activation of a Nerve Trunk Using a Transvascular Reshaping Lead”, U.S. Appl. No. 11/130,022, filed May 16, 2005, 33 pgs.
Caparso, Anthony, et al., “Vascularly Stabilized Peripheral Nerve Cup Assembly”, U.S. Appl. No. 11/151,103, filed Jun. 13, 2005, 41 pgs.
Chapleau, M W, et al., “Pulsatile activation of baroreceptors causes central facilitation of baroreflex”, American Journal of Physiology, 256(6 Pt 2), (Jun. 1989), H1735-41.
Chapleau, M. W., et al., “Contrasting effects of static and pulsatile pressure on carotid baroreceptor activity in dogs”, Circulation, vol. 61, No. 5, (Nov. 1987), 648-658.
Coleridge, J C, et al., “Relationship between pulmonary arterial pressure and impulse activity in pulmonary arterial baroreceptor fibres”, Journal of Physiology, 158, (Sep. 1961), 197-205.
Coleridge, J C, et al., “The distribution, connexions and histology of baroreceptors in the pulmonary artery, with some observations on the sensory innervation of the ductus arteriosus”, Journal of Physiology, 156, (May 1961), 591-602.
Cooper, Terry B, et al., “Neural effects on sinus rate and atrioventricular conduction produced by electrical stimulation from a transvenous electrode catheter in the canine right pulmonary artery”, Circulation Research, vol. 46, No. 1, (Jan. 1980), 48-57.
Courtice, G P, et al., “Effect of frequency and impulse pattern on the non-cholinergic cardiac response to vagal stimulation in the toad, Bufo marinus”, Journal of the Autonomic Nervous System, 48(3), (Aug. 1994), 267-72.
Cyberonics, “NeuroCybernetic Prosthesis System NCPA Pulse Generator Models 100 and 101”, Physician's Manual, (Aug. 2002), 1-146.
Dart, Jr., C H, et al., “Carotid sinus nerve stimulation treatment of angina refractory to other surgical procedures”, Annals of Thoracic Surgery, 11(4), (Apr. 1971), 348-59.
De Landsheere, D, et al., “Effect of spinal cord stimulation on regional myocardial perfusion assessed by positron emission tomography”, American Journal of Cardiology, 69(14), (May 1, 1992), 1143-9.
Dunning, A. J., “Electrostimulation of the Carotid Sinus Nerve in Angina Pectoris”, University Department of Medicine, Binnengasthuis, Amsterdam; Printed by Royal VanGorcum, Assen, Netherlands, (1971), 1-92.
Epstein, S. E., et al., “Treatment of angina pectoris by electrical stimulation of the carotid-sinus nerves”, New England Journal of Medicine, 280(18), (May 1, 1969), 971-978.
Farrehi, C, “Stimulation of the carotid sinus nerve in treatment of angina pectoris”, American Heart Journal, 80(6), (Dec. 1970), 759-65.
Feliciano, L, et al., “Vagal nerve stimulation releases vasoactive intestinal peptide which significantly increases coronary artery blood flow”, Cardiovascular Research, 40(1), (Oct. 1998), 45-55.
Fromer, M, et al., “Ultrarapid subthreshold stimulation for termination of atrioventricular node reentrant tachycardia”, Journal of the American College of Cardiology, 20(4), (Oct. 1992), 879-83.
Grassi, Guido, et al., “Baroreflex and non-baroreflex modulation of vagal cardiac control after myocardial infarction”, Am J Cardiol., 84(5), (Sep. 1, 1999), 525-529.
Griffith, Lawrence S.C., et al., “Electrical Stimulation of the Carotid Sinus Nerve in Normotensive and Renal Hypertensive Dogs”, Circulation, 28, (Jul.-Dec. 1963), 730.
Henning, R J, et al., “Effects of autonomic nerve stimulation, asynchrony, and load on dP/dtmax and on dP/dtmin”, American Journal of Physiology, 260(4 Pt 2), (Apr. 1991), H1290-H1298.
Henning, R J, et al., “Vagal nerve stimulation increases right ventricular contraction and relaxation and heart rate”, Cardiovascular Research, 32(5), (Nov. 1996), 846-53.
Henning, R J, et al., “Vagal stimulation attenuates sympathetic enhancement of left ventricular function”, American Journal of Physiology, 258(5 Pt 2), (May 1990), H1470-5.
Holder, L K, “Treatment of refractory partial seizures: preliminary results of a controlled study”, Pacing & Clinical Electrophysiology, 15(10 Pt 2), (Oct. 1992), 1557-71.
Holmgren, C., et al., “Risk of interference from transcutaneous electrical nerve stimulation on the sensing function of implantable defibrillators”, Pacing Clin Electrophysiol., 31(2), (Feb. 2008), 151-8.
Hood Jr., W B, et al., “Asynchronous contraction due to late systolic bulging at left ventricular pacing sites”, American Journal of Physiology, 217(1), (Jul. 1969), 215-21.
Ishise, H, et al., “Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure”, Journal of Applied Physiology, 84(4), (Apr. 1998), 1234-41.
Janes, R. D., et al., “Anatomy of human extrinsic cardiac nerves and ganglia.”, Am J Cardiol., 57(4), (Feb. 1, 1986), 299-309.
Jessurun, G A, et al., “Coronary blood flow dynamics during transcutaneous electrical nerve stimulation for stable angina pectoris associated with severe narrowing of one major coronary artery”, American Journal of Cardiology, 82(8), erratum appears in Am J Cardiol Feb. 15, 1999;83(4):642, (Oct. 15, 1998), 921-6.
Kandel, Eric R, et al., “Part VII: Arousal, Emotion, and Behavioral Homeostasis”, In: Principles of Neural Science, New York : McGraw-Hill, Health Professions Division, (2000), 966-969.
Karpawich, P P, et al., “Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block”, Pacing Clin Electrophysiol., 22(9), (Sep. 1999), 1372-7.
Kendrick, J E, “A comparison of the cardiovascular responses to stimulation of the aortic and carotid sinus nerves of the dog”, Proceedings of the Society for Experimental Biology & Medicine, 144(2), (Nov. 1973), 404-11.
Lacanette, Kerry, “A Basic Introduction to Filters—Active, Passive, and Switched-Capacitor”, National Semiconductor Corporation, http://www.swarthmore.edu/NatSci/echeeve1/Ref/DataSheet/Inttofilters.pdf, (Apr. 1991), 1-22.
Leclercq, C, et al., “Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing”, Am Heart J., 129(6), (Jun. 1995), 1133-41.
Leutmezer, F, et al., “Electrocardiographic Changes at the onset of Epileptic Seizures”, Epilepsia, 44(3), (2003), 348-354.
Levy, M. N., et al., “Effects of Repetitive Bursts of Vagal Activity on Heart Rate”, Circulation Research, 30(2), (1972), 186-195.
Li, M., et al., “Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats”, Circulation, 109(1), (2004), 120-124.
Libbus, I., “Integrated Lead for Applying Cardiac Resynchronization Therapy and Neural Stimulation Therapy”, U.S. Appl. No. 11/077,970, filed Mar. 11, 2005, 67 pgs.
Libbus, I., et al., “Method and Apparatus for Synchronizing Neural Simulation to Cardiac Cycles”, U.S. Appl. No. 11/099,141, filed Apr. 5, 2005, 36 pgs.
Libbus, I., “Safety Control System for Implantable Neural Stimulator”, U.S. Appl. No. 11/135,883, filed May 24, 2005, 43 pgs.
Libbus, I., et al., “System and Method for Closed-Loop Neural Stimulation”, U.S. Appl. No. 10/992,319, filed Nov. 18, 2004, 50 pgs.
Libbus, Imad, “Cardiac Rhythm Management Device With Neural Sensor”, U.S. Appl. No. 10/992,320, filed Nov. 18, 2004, 65 pgs.
Libbus, Imad, et al., “Cell Therapy and Neural Stimulation for Cardiac Repair”, U.S. Appl. No. 11/063,170, filed Feb. 22, 2005, 42 pgs.
Libbus, Imad, “Implantable Device for Treating Epilepsy and Cardiac Rhythm Disorders”, U.S. Appl. No. 11/312,178, filed Dec. 21, 2005, 39 pgs.
Libbus, Imad, et al., “Implantable Neural Stimulator With Mode Switching”, U.S. Appl. No. 11/137,038, filed May 25, 2005, 42 pgs.
Libbus, Imad, et al., “Method and Apparatus for Controlling Autonomic Balance Using Neural Stimulation”, U.S. Appl. No. 11/124,791, filed May 9, 2005, 47 pgs.
Libbus, Imad, “Method and Apparatus for Simultaneously Presenting Cardiac and Neural Signals”, U.S. Appl. No. 11/114,246, filed Apr. 25, 2005, 58 pgs.
Libbus, Imad, et al., “Neural Stimulation System to Prevent Simultaneous Energy Discharges”, U.S. Appl. No. 11/110,542, filed Apr. 20, 2005, 36 pgs.
Libbus, Imad, “Neural Stimulation With Avoidance of Inappropriate Stimulation”, U.S. Appl. No. 11/000,249, filed Nov. 30, 2004, 45 pgs.
Libbus, Imad, “Stimulator for Auricular Branch of Vagus Nerve”, U.S. Appl. No. 11/005,703, filed Dec. 7, 2004, 35 pgs.
Libbus, Imad, et al., “System and Method for Filtering Neural Stimulation”, U.S. Appl. No. 10/982,001, filed Nov. 4, 2004, 58 pgs.
Libbus, Imad, “System and Method to Deliver Therapy in Presence of Another Therapy”, U.S. Appl. No. 11/125,503, filed May 10, 2005, 39 pgs.
Libbus, Imad, “System to Provide Myocardial and Neural Stimulation”, U.S. Appl. No. 11/087,935, filed Mar. 23, 2005, 52 pgs.
Libbus, Imad, “System to Provide Neural Markers for Sensed Neural Activity”, U.S. Appl. No. 11/113,773, filed Apr. 25, 2005, 52 pgs.
Mannheimer, C, et al., “Epidural spinal electrical stimulation in severe angina pectoris”, British Heart Journal, 59(1), (Jan. 1988), 56-61.
Mannheimer, C, et al., “Transcutaneous electrical nerve stimulation (TENS) in angina pectoris”, Pain, 26(3), (Sep. 1986), 291-300.
Mannheimer, C, et al., “Transcutaneous electrical nerve stimulation in severe angina pectoris”, European Heart Journal, 3(4), (Aug. 1982), 297-302.
Martin, P., “Time-dependent heart period and contractility responses to successive brief vagal stimuli”, Am J Physiol, 239(4), (Oct. 1980), H494-H500.
Mazgalev, T N, et al., “Autonomic modification of the atrioventricular node during atrial fibrillation: role in the slowing of ventricular rate”, Circulation, 99(21), (Jun. 1, 1999), 2806-14.
McGregor, A., et al., “Right-Sided Vagus Nerve Stimulation as a Treatment for Refractory Epilepsy in Humans”, Epilepsia; 46(1), (Jan. 2005), 91-96.
Millar-Craig, M W, et al., “Circadian variation of blood-pressure”, Lancet, 1(8068), (Apr. 15, 1978), 795-7.
Minisi, A J, et al., “Regional left ventricular deafferentation increases baroreflex sensitivity following myocardial infarction”, Cardiovasc Res., 58(1), (Apr. 1, 2003), 136-41.
Moffitt, Julia, “Combined Neural Stimulation and Cardiac Resynchronization Therapy”, U.S. Appl. No. 11/078,460, filed Mar. 11, 2005, 35 pgs.
Moffitt, Julia, et al., “Neural Stimulator System for Cardiac Fat Pads”, U.S. Appl. No. 11/077,583, filed Mar. 11, 2005, 37 pgs.
Moffitt, Julia, et al., “System to Treat AV-Conducted Ventricular Tachyarrhythmia”, U.S. Appl. No. 11/099,226, filed Apr. 5, 2005, 39 pgs.
Moffitt, Julia, “Transvascular Neural Stimulation Device”, U.S. Appl. No. 11/103,245, filed Apr. 11, 2005, 33 pgs.
Murphy, D F, et al., “Intractable angina pectoris: management with dorsal column stimulation”, Medical Journal of Australia, 146(5), (Mar. 2, 1987), 260.
Neistadt, A, et al., “Effects of electrical stimulation of the carotid sinus nerve in reversal of experimentally induced hypertension”, Surgery, 61(6), (Jun. 1967), 923-31.
Nolan, J., et al., “Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure: Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart).”, Circulation, 98(15), (1998), 1510-1516.
Peters, T K, et al., “Temporal and spatial summation caused by aortic nerve stimulation in rabbits. Effects of stimulation frequencies and amplitudes”, Journal of the Autonomic Nervous System, 27(3), (Aug. 1989), 193-205.
Peters, T K, et al., “The principle of electrical carotid sinus nerve stimulation: a nerve pacemaker system for angina pectoris and hypertension therapy”, Annals of Biomedical Engineering, 8(4-6), (1980), 445-458.
Philbin, D M, et al., “Inappropriate shocks delivered by an ICD as a result of sensed potentials from a transcutaneous electronic nerve stimulation unit”, Pacing & Clinical Electrophysiology, 21(10), (Oct. 1998), 2010-1.
Prakash, P, et al., “Asymmetrical distribution of aortic nerve fibers in the pig”, Anat Rec., 158(1), (May 1967), 51-7.
Rosenqvist, M, et al., “The effect of ventricular activation sequence on cardiac performance during pacing”, Pacing and Electrophysiology, 19(9), (1996), 1279-1286.
Rugg-Gunn, F. J, et al., “Cardiac arrhythmias in focal epilepsy: a prospective long-term study.”, Lancet, 364(9452), (Dec. 18-31, 2004), 2212-9.
Rushmer, Robert F, “Chapter 5—Systemic Arterial Pressure”, In: Cardiovascular dynamics, Philadelphia : Saunders, (1976), 176-216.
Schauerte, P, et al., “Catheter stimulation of cardiac parasympathetic nerves in humans: a novel approach to the cardiac autonomic nervous system”, Circulation, 104(20), (Nov. 13, 2001), 2430-5.
Schauerte, P, et al., “Ventricular rate control during atrial fibrillation by cardiac parasympathetic nerve stimulation: a transvenous approach”, J Am Coll Cardiol., 34(7), (Dec. 1999), 2043-50.
Schauerte, P. N, et al., “Transvenous parasympathetic cardiac nerve stimulation: an approach for stable sinus rate control”, Journal of Cardiovascular Electrophysiology, 10(11), (Nov. 1999), 1517-1524.
Schauerte, P., et al., “Transvenous parasympathetic nerve stimulation in the inferior vena cava and atrioventricular conduction”, Journal of Cardiovascular Electrophysiology, 11(1), (Jan. 2000), 1 pg.
Scheiner, Avram, et al., “Leads for Pacing and/or Sensing the Heart From Within the Coronary Veins”, U.S. Appl. No. 11/600,807, filed Nov. 16, 2006, 43 pgs.
Scherlag, B. J, et al., “Endovascular stimulation within the left pulmonary artery to induce slowing of heart rate and paroxysmal atrial fibrillation.”, Cardiovasc Research, 54(2), (May 2002), 470-475.
Scherlag, M A., et al., “Endovascular Neural Stimulation Via a Novel Basket Electrode Catheter: Comparison of Electrode Configurations”, Journal of Interventional Cardiac Electrophysiology, 4(1), (Apr. 2000), 219-224.
Sigurdsson, A., et al., “The Role of Neurohormonal Activation in Chronic Heart Failure and Postmyocardial Infarction”, American Heart Journal, 132(1, Part 2), (Jul. 1996), 229-234.
Takahashi, N, et al., “Vagal modulation of ventricular tachyarrhythmias induced by left ansae subclaviae stimulation in rabbits”, Japanese Heart Journal, 39(4), (Jul. 1998), 503-11.
Thompson, Gregory W, “Bradycardia induced by intravascular versus direct stimulation of the vagus nerve”, Annals of Thoracic Surgery, 65(3), (Mar. 1998), 637-642.
Tse, H F, et al., “Long-term effect of right ventricular pacing on myocardial perfusion and function”, J Am Coll Cardiol., 29(4), (Mar. 15, 1997), 744-9.
Vanoli, E., et al., “Vagal Stimulation and Prevention of Sudden Death in Conscious Dogs With a Healed Myocardial Infarction”, Circulation Research, 68(5), (May 1991), 1461-1481.
Veerman, D P, et al., “Circadian profile of systemic hemodynamics”, Hypertension, 26(1), (Jul. 1995), 55-9.
Verity, M A, et al., “Plurivesicular nerve endings in the pulmonary artery”, Nature, 211(48), (Jul. 30, 1966), 537-8.
Verity, M, et al., “Pulmonary artery innervation: a morphopharmacologic correlation”, Proceedings of the Western Pharmacology Society, 8, (1965), 57-9.
Wallick, D W, et al., “Selective AV nodal vagal stimulation improves hemodynamics during acute atrial fibrillation in dogs”, American Journal of Physiology—Heart & Circulatory Physiology, 281(4), (Oct. 2001), H1490-7.
Waninger, M S, et al., “Electrophysiological control of ventricular rate during atrial fibrillation”, Pacing & Clinical Electrophysiology, 23(8), (Aug. 2000), 1239-44.
Wiggers, C J, et al., “The muscular reactions of the mammalian ventricles to artificial surface stimuli”, American Journal of Physiology, (1925), 346-378.
Zhang, Y, et al., “Optimal ventricular rate slowing during atrial fibrillation by feedback AV nodal-selective vagal stimulation”, American Journal of Physiology—Heart & Circulatory Physiology, 282(3), (Mar. 2002), H1102-10.
Zhou, X, et al., “Prevention of high incidence of neurally mediated ventricular arrhythmias by afferent nerve stimulation in dogs”, Circulation, 101(7), (Feb. 22, 2000), 819-24.
Related Publications (1)
Number Date Country
20140324114 A1 Oct 2014 US
Divisions (2)
Number Date Country
Parent 12148843 Apr 2008 US
Child 13397115 US
Parent 11125503 May 2005 US
Child 12148843 US
Continuations (2)
Number Date Country
Parent 13954342 Jul 2013 US
Child 14325634 US
Parent 13397115 Feb 2012 US
Child 13954342 US